Skip to main content
OpenTrials
Completed

NCT Number: NCT03738826

Reducing Disparities in Medication Adherence in SLE

This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erythematosus Autoimmune Diseases Behavior Connective Tissue Diseases Health Behavior Immune System Diseases Lupus Erythematosus, Systemic Medication Adherence Patient Acceptance of Health Care Patient Compliance Skin and Connective Tissue Diseases Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University

Durham, North Carolina, 27710, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All followup patients seen at the Duke Lupus clinic

Exclusion criteria

  • Patients not seen at the Duke Lupus Clinic
  • New patients seen for the first time at the Duke Lupus Clinic
  • Patients who are not prescribed any lupus medications

Treatment and study plan

behavioral intervention

Behavioral

Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.

Primary outcomes

  1. Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence

    Time frame: 12 weeks

    Feasibility as measured by documentation of adherence assessment made by provider.

  2. Acceptability as Measured by Provider Survey

    Time frame: 12 weeks

    Acceptability as measured by provider survey, score range 1-5, with a higher score indicating that the intervention was more acceptable.

Secondary outcomes

  1. Medication Adherence as Determined by Self Report

    Time frame: 12 weeks

  2. Percentage of Adherent Participants as Determined by Medication Possession Ratio (MPR)

    Time frame: Baseline, 12 weeks

    Medication Possession Ratio (MPR) = days with medication/total days. This will be determined by pharmacy refill data and calculated for 3 months (90 days). An MPR > or = 80% indicates adherence.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • National Institute on Minority Health and Health Disparities (NIMHD)
  • National Institutes of Health (NIH)

Registry information

Official study title

Reducing Disparities in Medication Adherence of Patients With Systemic Lupus Erythematosus (SLE)

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Nov 13, 2018
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.